Hypertrophic Cardiomyopathy Therapeutics Market to Become a Worth US$1.3 Bn by 2023
The global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market has been anticipated in a report penned by Transparency Market Research (TMR) to witness the dominance of industry players with a high sales rate. With that mentioned, generic players could make their presence known in the market but at a gradual pace. Leading players, viz. Merck & Co., Pfizer, Inc., and Sanofi S.A., have been foretold to account for a majority of the market share, which could reveal the significantly consolidated nature of the market....
View full press release